159 related articles for article (PubMed ID: 23785409)
1. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
[TBL] [Abstract][Full Text] [Related]
2. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer.
Kruczek K; Ratterman M; Tolzien K; Sulo S; Lestingi TM; Nabhan C
Br J Cancer; 2013 Oct; 109(7):1711-6. PubMed ID: 24008662
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
Yuan R; Kay A; Berg WJ; Lebwohl D
J Hematol Oncol; 2009 Oct; 2():45. PubMed ID: 19860903
[TBL] [Abstract][Full Text] [Related]
4. Infectious complications of vascular anomalies treated with sirolimus: A systematic review.
Kalbfell R; Cohen-Cutler S; Grisham E; Bereitschaft C; Borst AJ; Green AM; Willis DN; Yaeger L; Blatt J; Sisk BA
Pediatr Blood Cancer; 2024 Jan; 71(1):e30758. PubMed ID: 37933207
[TBL] [Abstract][Full Text] [Related]
5. Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature.
Lopez P; Kohler S; Dimri S
J Transplant; 2014; 2014():305931. PubMed ID: 25580277
[TBL] [Abstract][Full Text] [Related]
6. CPT-11 mitigates autoimmune diseases by suppressing effector T cells without affecting long-term anti-tumor immunity.
Liang H; Fan X; Cheng H; Ma X; Sun Y; Nan F; Zhou J; Shu P; Zhang W; Zuo F; Nakatsukasa H; Zhang D
Cell Death Discov; 2024 May; 10(1):218. PubMed ID: 38704362
[TBL] [Abstract][Full Text] [Related]
7. Perturbed autophagy intervenes systemic lupus erythematosus by active ingredients of traditional Chinese medicine.
Tian R; Yuan L; Huang Y; Zhang R; Lyu H; Xiao S; Guo D; Ali DW; Michalak M; Chen XZ; Zhou C; Tang J
Front Pharmacol; 2022; 13():1053602. PubMed ID: 36733375
[TBL] [Abstract][Full Text] [Related]
8. Protocadherin gamma C3: a new player in regulating vascular barrier function.
Kaupp V; Blecharz-Lang KG; Dilling C; Meybohm P; Burek M
Neural Regen Res; 2023 Jan; 18(1):68-73. PubMed ID: 35799511
[TBL] [Abstract][Full Text] [Related]
9. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies.
Lee L; Ramos-Alvarez I; Jensen RT
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267558
[No Abstract] [Full Text] [Related]
10.
Yamamoto K; Ioroi T; Shinomiya K; Yoshida A; Harada K; Fujisawa M; Omura T; Ikemi Y; Nakagawa S; Yonezawa A; Ogawa O; Matsubara K; Iwamoto T; Nishikawa K; Hayashi S; Tohara D; Murakami Y; Motoshima T; Jono H; Yano I
Oncol Res; 2022 May; 29(1):11-23. PubMed ID: 35016744
[TBL] [Abstract][Full Text] [Related]
11. Adverse Effects of Immunosuppression: Infections.
Handley G; Hand J
Handb Exp Pharmacol; 2022; 272():287-314. PubMed ID: 34671868
[TBL] [Abstract][Full Text] [Related]
12. IL13Rα2 Is Involved in the Progress of Renal Cell Carcinoma through the JAK2/FOXO3 Pathway.
Kang MA; Lee J; Lee CM; Park HS; Jang KY; Park SH
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33917914
[TBL] [Abstract][Full Text] [Related]
13. Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Ruiz-Camps I; Aguilar-Company J
Ther Adv Infect Dis; 2021; 8():2049936121989548. PubMed ID: 33680453
[TBL] [Abstract][Full Text] [Related]
14. mTOR and Aging: An Old Fashioned Dress.
Stallone G; Infante B; Prisciandaro C; Grandaliano G
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31174250
[TBL] [Abstract][Full Text] [Related]
15. mTOR: A Cellular Regulator Interface in Health and Disease.
Boutouja F; Stiehm CM; Platta HW
Cells; 2019 Jan; 8(1):. PubMed ID: 30609721
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.
Karavasilis V; Samantas E; Koliou GA; Kalogera-Fountzila A; Pentheroudakis G; Varthalitis I; Linardou H; Rallis G; Skondra M; Papadopoulos G; Papatsibas G; Sgouros J; Goudopoulou A; Kalogeras KT; Dervenis C; Pectasides D; Fountzilas G
Target Oncol; 2018 Dec; 13(6):715-724. PubMed ID: 30488350
[TBL] [Abstract][Full Text] [Related]
17. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.
Lee L; Ito T; Jensen RT
Expert Opin Pharmacother; 2018 Jun; 19(8):909-928. PubMed ID: 29757017
[TBL] [Abstract][Full Text] [Related]
18. Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis.
Wang L; Liu Y; Zhou W; Li W
Onco Targets Ther; 2017; 10():2281-2287. PubMed ID: 28490885
[TBL] [Abstract][Full Text] [Related]
19. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.
Kidd M; Modlin IM; Bodei L; Drozdov I
Cell Mol Gastroenterol Hepatol; 2015 Mar; 1(2):131-153. PubMed ID: 28210673
[TBL] [Abstract][Full Text] [Related]
20. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.
Perl A
Nat Rev Rheumatol; 2016 Mar; 12(3):169-82. PubMed ID: 26698023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
